Annual Drug Patent Expirations for JANUMET
Janumet is a drug marketed by Merck Sharp Dohme and is included in two NDAs. It is available from two suppliers. There are four patents protecting this drug and three Paragraph IV challenges.
Drug patent litigation for JANUMET.
The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. Two suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
